Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241086 | 0.86 | P2RX7 (0.46) | BRD4ARCYP1A2SMN1; SMN2P2RX7 | |
| SCHEMBL5632658 | 0.85 | KDM4E (0.44) | BRD4GABRA2GABRB2SMN1; SMN2KDM4E | |
| SCHEMBL4419725 | 0.84 | BRD4 (0.67) | BRD4GABRB2CYP19A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19925602 | 0.84 | BRD4 (0.80) | BRD4 | |
| SCHEMBL19284340 | 0.81 | GABRA2 (0.46) | BRD4GABRA2GABRB2SMN1; SMN2KDM4E | |
| SCHEMBL13437651 | 0.80 | CYP19A1 (0.61) | BRD4GABRA2GABRB2CYP19A1ALDH1A1 | |
| SCHEMBL1314260 | 0.79 | GABRA2 (0.51) | GABRA2GABRB2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL29194233 | 0.76 | DRD2 (0.47) | SMN1; SMN2P2RX7ALDH1A1HPGD | |
| SCHEMBL22122015 | 0.75 | GABRA2 (0.41) | BRD4GABRA2GABRB2SMN1; SMN2KDM4E | |
| SCHEMBL9786782 | 0.75 | BRD4 (0.63) | BRD4GABRB2CYP1A2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606255-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2098508-A1 | Cyclic derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| EP-1606255-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1606255-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | BRD4 2518/4885GABRA2 1953/4885GABRB2 1870/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | BRD4 2385/4885GABRA2 2219/4885GABRB2 2123/4885 |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | BRD4 2518/4885GABRA2 1953/4885GABRB2 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.